During the last session, Inhibrx Biosciences Inc. (NASDAQ:INBX)’s traded shares were 0.3 million. At the end of the trading day, the stock’s price was $16.28, reflecting an intraday loss of -6.92% or -$1.21. The 52-week high for the INBX share is $18.95, that puts it down -16.4 from that peak though still a striking 33.66% gain since the share price plummeted to a 52-week low of $10.80. The company’s market capitalization is $235.73M, and the average intraday trading volume over the past 10 days was 0.12 million shares, and the average trade volume was 139.51K shares over the past three months.
Inhibrx Biosciences Inc. (NASDAQ:INBX) trade information
Inhibrx Biosciences Inc. (INBX) registered a -6.92% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.92% in intraday trading to $16.28, hitting a weekly high. The stock’s 5-day price performance is -0.79%, and it has moved by 24.75% in 30 days. The short interest in Inhibrx Biosciences Inc. (NASDAQ:INBX) is 0.7 million shares and it means that shorts have 7.29 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inhibrx Biosciences Inc. (INBX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -94.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be nan as predicted by 1.0 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to nan by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled nan and 1.63M respectively.
INBX Dividends
Inhibrx Biosciences Inc. is due to release its next quarterly earnings on 2024-Aug-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Inhibrx Biosciences Inc. (NASDAQ:INBX)’s Major holders
Inhibrx Biosciences Inc. insiders own 23.55% of total outstanding shares while institutional holders control 67.42%, with the float percentage being 88.19%. DEKABANK DEUTSCHE GIROZENTRALE is the largest shareholder of the company, while 127.0 institutions own stock in it. As of 2024-06-30, the company held over 26400.0 shares (or 0.0484% of all shares), a total value of $0.93 million in shares.
The next largest institutional holding, with 6690.0 shares, is of ADVISOR GROUP HOLDINGS, INC.’s that is approximately 0.0123% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.23 million.
Also, the Mutual Funds coming in first place with the largest holdings of Inhibrx Biosciences Inc. (INBX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 304.07 shares. This amounts to just over 2.10 percent of the company’s overall shares, with a $4.95 million market value. The same data shows that the other fund manager holds slightly less at 285.39, or about 1.97% of the stock, which is worth about $4.65 million.
